Physician profile
Mark A Snyder
NPI 1811949530
$2,063.73
in general payments reported to CMS, 2019-2025
15 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $18.46 · 2021: $454 · 2022: $293 · 2023: $108 · 2024: $674 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $379.45 | 2022-2024 | Xiidra, Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $366.09 | 2019-2021 | |
| Alcon Vision LLC | $269.31 | 2021-2025 | Precision 1, Total30, Precision7 |
| Glaukos Corporation | $162.72 | 2024 | Radius |
| Tarsus Pharmaceuticals, INC. | $125.21 | 2025 | |
| Kala Pharmaceuticals, INC. | $116.15 | 2020-2021 | |
| Shire North American Group INC | $106.53 | 2019 | |
| Allergan, INC. | $103.03 | 2021 | |
| Sun Pharmaceutical Industries INC. | $98.70 | 2021 | |
| Dompe US, INC. | $97.46 | 2024 | Oxervate |
| Abbvie INC. | $79.93 | 2022 | |
| Coopervision INC. | $77.30 | 2024 | Cvi Contact Lens |
| Lombart Brothers, INC. | $36.03 | 2024 | Opd-III |
| Mallinckrodt Hospital Products INC. | $24.59 | 2025 | Acthar |
| Maculogix, INC. | $21.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.